Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses
Long-term treatment with linvoseltamab 200 mg provided deep and durable responses, with no new safety signals, and thus represents an effective therapeutic option in RRMM.
Authors
- Michelle DeVeaux
- Mansi R. Shah (ORCID: https://orcid.org/0000-0001-8884-3085)
- Karen Rodriguez Lorenc
- Ja Min Byun (ORCID: https://orcid.org/0000-0003-1780-5553)
- Matthew J. Pianko (ORCID: https://orcid.org/0000-0001-9295-9750)
- Naresh Bumma
- Rebecca Silbermann (ORCID: https://orcid.org/0000-0002-7571-1523)
- Sundar Jagannath (ORCID: https://orcid.org/0000-0003-2934-6518)
- Joshua Ryan Richter (ORCID: https://orcid.org/0000-0002-0274-0585)
- Suzanne Lentzsch (ORCID: https://orcid.org/0000-0003-1708-7344)
- Megan Seraphin (ORCID: https://orcid.org/0000-0002-9582-2909)
- Joaquín Martínez‐López (ORCID: https://orcid.org/0000-0001-7908-0063)
- Jeffrey A. Zonder (ORCID: https://orcid.org/0000-0002-1741-2795)
- Marie‐Christiane Vekemans (ORCID: https://orcid.org/0000-0001-5198-495X)
- Markus Munder (ORCID: https://orcid.org/0000-0003-4947-8796)
- Ka Lung Wu (ORCID: https://orcid.org/0000-0001-6042-978X)
- Jing Christine Ye
- Anita Boyapati (ORCID: https://orcid.org/0000-0003-1375-2722)
- Hans Chulhee Lee (ORCID: https://orcid.org/0000-0001-8545-3292)
- Attaya Suvannasankha (ORCID: https://orcid.org/0000-0001-9445-8781)
- Glenn Scott Kroog (ORCID: https://orcid.org/0009-0000-2897-9810)
- Katherine L. B. Knorr (ORCID: https://orcid.org/0000-0001-5843-9057)
- Rachid Baz (ORCID: https://orcid.org/0000-0003-4538-4733)
- Tito Roccia (ORCID: https://orcid.org/0009-0000-3466-1112)
- Dhruti Chokshi
- Madhav V. Dhodapkar (ORCID: https://orcid.org/0000-0002-8249-5988)
- James E. Hoffman (ORCID: https://orcid.org/0009-0003-8663-7001)
- Joseph Maly
- Swathi Namburi
- Anasuya Hazra
- Chang‐Ki Min
Institutions
- Rutgers, The State University of New Jersey (US)
- Indiana University Health (US)
- Cliniques Universitaires Saint-Luc (BE)
- The University of Texas MD Anderson Cancer Center (US)
- Emory University (US)
- Oregon Health & Science University (US)
- Regeneron (United States) (US)
- Johannes Gutenberg University Mainz (DE)
- Norton Healthcare (US)
- Columbia University Irving Medical Center (US)
- Seoul National University Hospital (KR)
- Moffitt Cancer Center (US)
- The Barbara Ann Karmanos Cancer Institute (US)
- Hospital Universitario 12 De Octubre (ES)
- University of Miami Health System (US)
- Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie (DE)
- Richard L. Roudebush VA Medical Center (US)
- Center for Cancer and Blood Disorders (US)
- Michigan Center for Translational Pathology (US)
- Ziekenhuisnetwerk Antwerpen Stuivenberg (BE)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- The Ohio State University (US)
- Indiana University – Purdue University Indianapolis (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2025-11-15
- DOI
- https://doi.org/10.1016/j.clml.2025.11.004
- Citations
- 3
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.31
Funders
- Regeneron Pharmaceuticals